Frontera Therapeutics
Frontera Therapeutics develops gene therapy medicines using the APEX Technology & Manufacturing Platform, with a pipeline addressing both orphan and larger patient markets. The company has initiated Phase II clinical trials for FT-001 and received Orphan Drug Designation for FT-002 from the U.S. FDA.
Services
Frontera Therapeutics specializes in developing gene therapy medicines aimed at improving the lives of patients. Their innovative treatments cover a range of disease areas including ophthalmology, hematology, cardiovascular, and metabolic diseases. The company's targeted approach involves utilizing their APEX Technology & Manufacturing Platform, a state-of-the-art adeno-associated virus (AAV) gene expression system, to deliver precise gene therapies.
Technology and Manufacturing
Frontera Therapeutics employs the APEX Technology & Manufacturing Platform for their gene therapies. This innovative platform is an adeno-associated virus (AAV) gene expression system that allows for efficient gene delivery. Their process is supported by state-of-the-art Good Manufacturing Practice (GMP) facilities, ensuring that their products meet rigorous quality and safety standards.
Clinical Trials and Pipeline
Frontera Therapeutics has initiated Phase II clinical trials for their product FT-001 aimed at treating hereditary retinopathy. Their pipeline also includes FT-002, which has received Orphan Drug Designation from the U.S. FDA for the treatment of Inherited Retinal Dystrophies caused by RPGR gene variants. Additionally, FT-003 was the first gene therapy for Diabetic Macular Edema (DME) to be dosed in a patient in China. These efforts reflect the company's commitment to addressing both orphan diseases and larger patient markets.
Product Development
Frontera Therapeutics is actively developing a range of gene therapy products. Their product FT-001 is in Phase II clinical trials for the treatment of hereditary retinopathy, while FT-002 targets Inherited Retinal Dystrophies caused by RPGR gene variants and has received Orphan Drug Designation. FT-003 focuses on Diabetic Macular Edema (DME) and was first dosed in a patient in China. These products highlight the company's focus on combining cutting-edge technology with rigorous clinical research to offer new treatment options for significant medical conditions.
